Kezar life sciences, inc. (KZR)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-10,012

-9,579

-9,148

-8,718

-7,642

-5,782

-5,663

-6,775

-4,947

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

362

340

333

325

303

204

205

194

87

Stock-based compensation

1,173

1,007

1,090

1,009

901

449

430

988

126

Amortization of premiums and discounts on marketable securities

96

83

201

336

359

-

-

-

-

Loss on disposal of property and equipment

-

-

-

-

-

-9

0

0

-97

Changes in operating assets and liabilities
Prepaid expenses, other current assets and other long-term assets

256

-

747

158

282

-

323

308

641

Accounts payable, accrued liabilities and other current liabilities

739

-

-

-

560

-

-

-

-

Other assets

-

-

-

-

-

-

-

-22

-39

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-480

1,028

Other liabilities, current

-

-

-

-

-

-

-

-157

149

Deferred rent

-

-

-

-

-

79

79

433

-296

Operating lease liabilities

211

-

197

193

181

-

-

-

-

Net cash used in operating activities

-8,301

-7,210

-8,255

-7,712

-6,700

-5,473

-4,604

-6,949

-3,766

Cash flows from investing activities:
Purchases of property and equipment

93

18

66

489

34

117

88

720

195

Purchases of marketable securities

72,518

15,684

27,316

23,319

35,936

-

-

-

-

Maturities of marketable securities

33,281

17,380

43,005

25,950

36,946

-

-

-

-

Net cash (used in) provided by investing activities

-39,330

1,678

15,623

2,142

976

-9,916

-56,671

-17,122

-195

Cash flows from financing activities:
Proceeds from sale of common stock and pre-funded warrants in underwritten offering, net of offering costs

53,365

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock under employee stock incentive plans

3

-

-

-

4

-

-

-

-

Proceeds from the exercise of stock options

-

-

-

-

-

-

-

188

25

Net cash provided by financing activities

53,368

80

8

180

4

5

-1,087

78,970

25

Effect of exchange rate changes on cash and cash equivalents

-117

38

-42

-49

8

-28

-17

-24

-12

Net increase (decrease) in cash and cash equivalents

5,620

-5,414

7,334

-5,439

-5,712

-15,412

-62,379

54,875

-3,948

Supplemental disclosures of noncash investing and financing information:
Reclassification of employee stock liability to equity upon vesting

10

13

12

13

12

40

5

7

17

Addition of tenant improvement paid by landlord

-

-

-

-

-

0

0

649

2,054

Purchase of property and equipment in accounts payable

-

-

-6

-400

423

31

-28

14

21

Unpaid offering costs in accrued liabilities

5

-

-

-

-

-

-

-

-

Deferred offering costs in accrued liabilities

-

-

-

-

-

-

-

-159

1,300